Сравнение
Degarelix vs. Glepaglutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
214766-78-6
нет данных
Молекулярная масса
1632.3 g/mol
нет данных
Период полувыведения
1320 h
нет данных
Последовательность
Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-Ilys-Pro-D-Ala-NH2нет данных
Механизм действия
Degarelix
Degarelix is a competitive GnRH receptor antagonist. It binds reversibly and immediately to the pituitary GnRH receptors and blocks their activation. This rapidly suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn lowers testosterone production in the testes. Unlike GnRH agonists (e.g., leuprorelin), which first cause a transient stimulation with a testosterone surge (flare), this direct antagonism lacks the initial stimulation phase, so testosterone declines without a preceding rise. This mechanism underlies the literature-described use in hormone-dependent prostate cancer.
Glepaglutide
As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
1
из них на людях
4
1
Зафиксированные эффекты
4
2
Открытые противоречия
1
0
Задокументированные нежелательные явления
2
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Degarelix and Glepaglutide?
- Degarelix is classified as "Исследования (прочее)", while Glepaglutide is classified as "Исследования (прочее)". Degarelix: Degarelix (trade name Firmagon) is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) receptor antagonist. Unlike GnRH agonists, it blocks the receptor directly and does not trigger an initial testosterone surge (flare). It is an approved prescription medicine for the treatment of advanced, hormone-dependent prostate cancer. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Degarelix or Glepaglutide?
- The highest available evidence level is "РКИ на людях" for Degarelix and "РКИ на людях" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Degarelix and Glepaglutide in Germany and the United States?
- Германия: Degarelix — Рецептурный, Glepaglutide — Не одобрено. США: Degarelix — Рецептурный, Glepaglutide — Не одобрено. These are factual summaries with source and review date on the individual pages.